HALO

Business Context and Reporting Period

Company: Halozyme Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Halozyme is a biopharmaceutical company developing recombinant human enzymes (rHuPH20) for drug delivery, palliative care, oncology, and infertility. The company transitioned from a development-stage organization to a commercial entity in June 2005 with the launch of Cumulase (IVF). Key products include Cumulase (marketed), Hylenex (FDA approved, marketed via partner), and Chemophase (oncology, Phase I/IIa).

Key Financial Metrics

Note: The company has no long-term debt or capital lease obligations as of December 31, 2006. The significant increase in deferred revenue is primarily due to a $20 million upfront payment from Roche.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 672% to $981,746, driven by product sales ($670,625 vs. $127,209) and new revenue from collaborative agreements ($311,121 vs. $0).
• Operating Expenses: SG&A expenses increased 102% to $6.9 million, largely due to share-based compensation ($850,000), increased professional fees, and marketing costs. R&D expenses decreased 10% to $9.2 million due to reduced contract manufacturing and toxicology study costs, partially offset by higher clinical trial costs.
• Liquidity: Cash and cash equivalents increased by $25.1 million to $44.2 million. This was driven by the $20 million Roche upfront payment, $11.1 million in net proceeds from a stock sale to Roche, and $7.3 million from warrant/option exercises.
• Net Loss: Net loss increased to $14.8 million from $13.3 million, primarily due to higher operating expenses despite revenue growth.

Guidance, Outlook, and Risks

Strategic Developments:

• Roche Agreement (Dec 2006): Entered a license and collaboration for Enhanze Technology. Received $20 million upfront (deferred revenue) with potential milestones up to $111 million plus royalties. Roche also purchased $11.1 million of common stock.
• Baxter Agreement (Feb 2007 - Subsequent Event): Amended agreements for Hylenex. Baxter paid $10 million upfront, prepaid $1 million in royalties, and committed to prepay $9 million by Jan 1, 2009. Baxter assumed all development and marketing costs. Baxter also purchased $20 million of common stock.

Outlook: Management believes current cash resources ($44.2 million) are sufficient to fund operations for at least the next 12 months. The company anticipates significant future R&D expenses as it advances Chemophase and other candidates.

Risks and Contingencies:

• Profitability: The company has a history of net losses and may never achieve profitability. Accumulated deficit is $41.1 million.
• Regulatory Approval: Future revenue depends on FDA approval for Chemophase and other candidates. Failure to obtain approval would materially impair the business.
• Manufacturing Dependence: Reliance on a single contract manufacturer (Avid Bioservices) for active pharmaceutical ingredients and Baxter for fill/finish of Hylenex.
• Market Acceptance: Products are priced at a premium to animal-derived competitors; market penetration is uncertain.

Investor Verification Checklist

• Deferred Revenue Recognition: Verify the amortization schedule for the $20 million Roche upfront payment and the $10 million Baxter upfront payment (subsequent event) to understand future revenue streams.
• Product Sales Volume: Confirm the volume and pricing of Cumulase and Hylenex API sales to assess the sustainability of the $670k product revenue.
• Chemophase Clinical Progress: Monitor the results of the Phase I/IIa clinical trials for Chemophase, as this is the primary oncology pipeline asset.
• Manufacturing Capacity: Assess the capacity and performance of Avid Bioservices to ensure supply chain stability for Cumulase and Hylenex.
• Share-Based Compensation: Review the impact of the new SFAS 123(R) accounting standard on future expense recognition ($2.2 million unrecognized costs remaining).